Our work has shown ARCA can detect a trend in CD34+VEGFR2+CD45– EPCs between NV-ARMD and NNV-ARMD subjects, and this should serve as a foundation for moving forward with prospective trials. The gene discussed is CD34; the disease is age-related macular degeneration.